Prudential Financial Inc. raised its holdings in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 23.2% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 3,488,992 shares of the biopharmaceutical company’s stock after purchasing an additional 657,016 shares during the period. Prudential Financial Inc. owned approximately 0.21% of Bristol-Myers Squibb worth $222,389,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also modified their holdings of BMY. Tradewinds Capital Management LLC raised its holdings in Bristol-Myers Squibb by 34.6% in the 2nd quarter. Tradewinds Capital Management LLC now owns 1,945 shares of the biopharmaceutical company’s stock worth $108,000 after purchasing an additional 500 shares during the period. Atlantic Trust LLC bought a new position in Bristol-Myers Squibb in the 2nd quarter worth $111,000. American National Bank raised its holdings in Bristol-Myers Squibb by 11.7% in the 2nd quarter. American National Bank now owns 2,144 shares of the biopharmaceutical company’s stock worth $119,000 after purchasing an additional 225 shares during the period. Blue Chip Partners Inc. raised its holdings in Bristol-Myers Squibb by 0.7% in the 2nd quarter. Blue Chip Partners Inc. now owns 2,156 shares of the biopharmaceutical company’s stock worth $120,000 after purchasing an additional 15 shares during the period. Finally, BDO Wealth Advisors LLC bought a new position in Bristol-Myers Squibb in the 2nd quarter worth $123,000. Institutional investors and hedge funds own 69.75% of the company’s stock.
Bristol-Myers Squibb Co (NYSE BMY) opened at $63.28 on Tuesday. The company has a market capitalization of $103,570.00, a PE ratio of 24.91, a P/E/G ratio of 2.16 and a beta of 1.18. Bristol-Myers Squibb Co has a 12-month low of $46.01 and a 12-month high of $66.10. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.59 and a quick ratio of 1.46.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, February 1st. Shareholders of record on Friday, January 5th will be paid a $0.40 dividend. The ex-dividend date of this dividend is Thursday, January 4th. This represents a $1.60 annualized dividend and a yield of 2.53%. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 62.99%.
In other news, EVP Sandra Leung sold 156,582 shares of Bristol-Myers Squibb stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $63.37, for a total transaction of $9,922,601.34. Following the completion of the sale, the executive vice president now owns 584,373 shares of the company’s stock, valued at $37,031,717.01. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Theodore R. Samuels II purchased 4,000 shares of the firm’s stock in a transaction dated Friday, December 15th. The shares were bought at an average cost of $62.30 per share, with a total value of $249,200.00. Following the purchase, the director now directly owns 22,000 shares of the company’s stock, valued at approximately $1,370,600. The disclosure for this purchase can be found here. 0.23% of the stock is owned by company insiders.
A number of brokerages have issued reports on BMY. UBS Group reiterated a “buy” rating and issued a $72.00 price target (up previously from $62.00) on shares of Bristol-Myers Squibb in a research note on Friday, October 6th. Vetr upgraded Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $67.92 price target for the company in a research note on Monday, October 9th. Zacks Investment Research lowered Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Thursday, November 2nd. Citigroup raised their price objective on Bristol-Myers Squibb to $72.00 and gave the company a “buy” rating in a research report on Wednesday, October 18th. Finally, BMO Capital Markets set a $49.00 price objective on Bristol-Myers Squibb and gave the company a “sell” rating in a research report on Thursday, October 12th. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have given a buy rating to the company’s stock. Bristol-Myers Squibb has a consensus rating of “Hold” and a consensus target price of $65.11.
ILLEGAL ACTIVITY NOTICE: This article was originally published by BBNS and is the property of of BBNS. If you are reading this article on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright law. The legal version of this article can be viewed at https://baseballnewssource.com/markets/prudential-financial-inc-has-222-39-million-holdings-in-bristol-myers-squibb-co-bmy/1817609.html.
Bristol-Myers Squibb Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.